Introduction
Ticagrelor, a direct-acting and reversible P2Y 12 -adenosine diphosphate receptor antagonist, is recommended as a firstline antithrombotic agent in patients with acute coronary syndromes. 1 The superiority of ticagrelor over other P2Y 12 antagonists is thought to be mediated in part by pleiotropic properties associated with an increased concentration of adenosine, including cardioprotection, anticoagulant effects, and anti-inflammatory properties. 2 However, these pleiotropic properties can also be responsible for major adverse effects, including electrophysiological consequences. Herein, we describe the case of a patient with severe cyclical sinus bradycardia and atrioventricular (AV) block related to ticagrelor.
Case report
A 75-year-old woman presented with an acute coronary syndrome. She had known coronary artery disease with balloon angioplasty and stenting of the left anterior descending and circumflex arteries 7 years prior. Her past medical history was remarkable for hypertension, dyslipidemia, diabetes mellitus, and obesity. Her electrocardiogram during chest pain showed diffuse ST-segment depression. After she received a loading dose of 180 mg of ticagrelor along with 325 mg of aspirin, urgent coronary angiography revealed multivessel disease with chronic total occlusion of the right coronary artery and severe stenosis of the left main and circumflex arteries. Two new-generation drug-eluting stents were implanted, with excellent angiographic results. Her postprocedural left ventricle ejection fraction was 50%, with mild mitral regurgitation.
A few hours after the percutaneous coronary intervention, the patient developed Cheyne-Stokes respiration in the absence of overt heart failure, with marked sinus arrhythmia ( Figure 1 ). Sinus tachycardia and severe sinus bradycardia , 30 beats/min were recorded during apneic and hyperpneic phases, respectively. As the pattern intensified, cyclical transient complete AV block occurred with up to 5-second pauses. Work-up including electrolytes, creatinine clearance, liver enzymes, and thyroid function was unrevealing.
Maintenance therapy with ticagrelor 90 mg orally twice daily was discontinued and clopidogrel introduced. Metoprolol was also suspended. A notable improvement was observed within 24 hours, with less pronounced sinus bradycardia and absence of AV block. The beta-blocker was reinstated and was well tolerated. The patient was discharged 2 days later following complete resolution of cyclical bradyarrhythmias. An electrophysiology study was not performed considering the presumed iatrogenic mechanism, prompt recovery, and normal electrocardiogram. At 1-month follow-up, the absence of a recurrent bradyarrhythmia was confirmed by 24-hour Holter monitoring.
Discussion
In the setting of an acute coronary syndrome, the differential diagnosis considered included ischemia of the conduction system and ischemia-provoked autonomic dysfunction. However, the time course, with onset of the bradyarrhythmia following ticagrelor loading and rapid recovery upon cessation of therapy, favored the diagnosis of an adverse pharmacologic effect. Bradycardia related to ticagrelor was first described in a phase IIb dose-ranging study, where a post hoc analysis of cardiac arrhythmias revealed an unexpected increased incidence of predominantly asymptomatic ventricular pauses. 3 These findings were corroborated by the prospective PLATO (Platelet Inhibition and Patient Outcomes) trial. 4 Among 2908 patients with 7-day electrocardiographic monitoring at the time of randomization and again at 1 month, ventricular pauses 3 seconds occurred more frequently in patients receiving ticagrelor compared to clopidogrel during the first week (5.8% vs 3.6%, relative risk 1.61, P 5 .006). Most pauses were asymptomatic, of sinoatrial origin, and nocturnal. However, no significant difference was observed in recorded bradyarrhythmias at 1 month and there were no apparent clinical bradycardic events during follow-up. 4 KEYWORDS Adenosine; AV block; Coronary artery disease; Sinus node dysfunction; Ticagrelor (Heart Rhythm Case Reports 2018;4:527-529) Dr Khairy is supported by a research chair in electrophysiology and congenital heart disease. Address reprint requests and correspondence: Dr Paul Khairy, Montreal Heart Institute, 5000 Belanger St E, Montreal, QC, Canada, H1T 1C8. E-mail address: paul.khairy@umontreal.ca.
The effect of ticagrelor on sinoatrial and AV nodes is believed to be mediated by an increased tissue concentration of adenosine. Animal experiments and in vitro models demonstrated that ticagrelor interferes with adenosine metabolism, resulting in increased adenosine concentrations via inhibition of adenosine uptake by erythrocytes. 5 This is most likely due to inhibition of sodium-independent equilibrative nucleoside transporters. 5 Consistently, in the clinical realm, ticagrelor has been associated with increased coronary blood flow velocity in patients with acute coronary syndromes, providing a plausible mechanistic explanation for its off-target cardioprotective effects. 6, 7 The adenosine-related hypothesis can also explain the predominance of ticagrelor-associated nocturnal pauses due to an increased local adenosine concentration that enhances vagal-mediated nocturnal bradycardia. Few reports of clinically significant ticagrelor-related bradycardia requiring drug discontinuation have been published. 8 To the best of our knowledge, we report the first case of severe sinus respiratory arrhythmia combined with AV block after ticagrelor loading. Cheyne-Stokes respiration frequently occurs in patients with congestive heart failure 9 and has been associated with exaggerated respiratory heart rate variations. 10 While our patient had no evidence of heart failure, emerging reports suggest that ticagrelor may itself induce central sleep apnea and Cheyne-Stokes respiration.
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The pathophysiological explanation remains unclear. Proposed mechanisms include antagonism of microglial P2Y 12 receptors and effects on pulmonary C fibers, either as a result of increased adenosine tissue levels or because of putative P2Y 12 receptors on pulmonary C fibers.

Conclusion
This report demonstrates that, although rare, ticagrelor can induce significant bradyarrhythmias. Electrophysiologists should, therefore, be aware of this reversible cause of sinus node dysfunction and AV block in order to manage patients appropriately and avoid unnecessary pacemakers. As this case illustrates, it is possible that the combination of ticagrelor-induced Cheyne-Stokes respiration and bradyarrhythmias can provoke a more severe phenotype consisting of cyclical severe sinus bradycardia with concomitant AV block.
KEY TEACHING POINTS
The antithrombotic agent ticagrelor is a P2Y 12 -adenosine diphosphate receptor antagonist. It inhibits adenosine uptake by erythrocytes, thereby resulting in increased adenosine tissue concentrations.
Sinus bradycardia and atrioventricular (AV) block are electrophysiological side effects that are reversible upon cessation of ticagrelor.
Ticagrelor can also induce central sleep apnea with Cheyne-Stokes respiration, which may contribute to a cyclical pattern of sinus node dysfunction and AV block. Figure 1 Cheyne-Stokes respiration with cyclical sinus bradycardia and atrioventricular (AV) block. Shown are electrocardiographic tracings from telemetry leads II and V along with the corresponding respiratory rate (RR). In the upper panel, sinus tachycardia is seen as the respiratory rate slows toward apnea. As respiration resumes and progresses toward hyperpnea, AV block follows in the lower panel, with nonconducted P waves indicated by the arrows.
